BioCardia Receives Buy Rating from HC Wainwright
BCDA Stock | USD 2.26 0.13 6.10% |
About 74 percent of all Biocardia's investors are curious in acquiring. The analysis of the overall investor sentiment regarding Biocardia suggests that a large number of traders are confidant. The current market sentiment, together with Biocardia's historical and current headlines, can help investors time the market. In addition, many technical investors use Biocardia stock news signals to limit their universe of possible portfolio assets.
Biocardia |
HC Wainwright reiterated their buy rating on shares of BioCardia in a research report released on Thursday morning,Benzinga reports. They currently have a 25.00 target price on the stock. BioCardia Trading Down 4.0 percent BioCardia stock traded down 0.08 during trading on Thursday, reaching 1.94. The company had a trading volume
Read at thelincolnianonline.com
Biocardia Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Biocardia can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Biocardia Fundamental Analysis
We analyze Biocardia's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biocardia using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biocardia based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Biocardia is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Biocardia Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biocardia stock to make a market-neutral strategy. Peer analysis of Biocardia could also be used in its relative valuation, which is a method of valuing Biocardia by comparing valuation metrics with similar companies.
Peers
Biocardia Related Equities
ANTX | AN2 Therapeutics | 8.94 | ||||
PTIX | Protagenic Therapeutics | 6.56 | ||||
MLYS | Mineralys Therapeutics, | 5.22 | ||||
ERAS | Erasca | 3.85 | ||||
NGENF | NervGen Pharma | 3.35 | ||||
FBRX | Forte Biosciences | 2.30 | ||||
AVTE | Aerovate Therapeutics | 1.92 | ||||
KTTA | Pasithea Therapeutics | 1.89 | ||||
ACRV | Acrivon Therapeutics, | 1.71 | ||||
RZLT | Rezolute | 1.03 | ||||
ADAG | Adagene | 0.00 | ||||
ANEB | Anebulo Pharmaceuticals | 2.67 | ||||
ABVC | ABVC Biopharma | 3.51 | ||||
INDP | Indaptus Therapeutics | 4.76 |
Complementary Tools for Biocardia Stock analysis
When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |